Stephen Amato

Stephen Amato is the interim Head of Investor Relations at Biogen. Dr. Amato joined Biogen in 2019 and has more than a decade of experience across different areas of biopharmaceutical drug development, holding various roles in research, development and operations in both early-stage companies and large corporations. Dr. Amato has been a member of the Biogen investor relations team since 2020 where he has helped lead global investor relations functions, as well as operations planning and analysis.  

He began his biopharmaceutical career as a postdoctoral fellow at Pfizer, where he worked to identify novel therapeutics for neuropsychiatric indications, including schizophrenia. Immediately prior to joining Biogen, Dr. Amato worked as a project lead in Pfizer’s clinical development unit.

Dr. Amato earned his Ph.D. from Boston University in cellular and molecular biology.